Trials / Conditions / Borderline Resectable Pancreatic Ductal Adenocarcinoma
Borderline Resectable Pancreatic Ductal Adenocarcinoma
6 registered clinical trials studyying Borderline Resectable Pancreatic Ductal Adenocarcinoma — 6 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Recruiting | NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar T NCT06821997 | Roswell Park Cancer Institute | Phase 2 |
| Recruiting | Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment NCT06574620 | British Columbia Cancer Agency | N/A |
| Recruiting | PULSAR in Systemic Therapy for Pancreatic Cancer NCT07269626 | Samsung Medical Center | Phase 2 |
| Recruiting | Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline NCT06423326 | Emory University | Phase 2 |
| Recruiting | Determining the Link Between Dietary Patterns, Fecal Microbiome and Response to Neoadjuvant Chemotherapy NCT06595160 | Emory University | — |
| Recruiting | Targeted Pathway Inhibition in Patients With Pancreatic Cancer NCT04005690 | OHSU Knight Cancer Institute | EARLY_Phase 1 |